Clinicopathologic features and treatment options of ocular adnexal lymphoma

Abstract

There has been considerable interest, in the recent literature, in ocular adnexal lymphomas (OALs) and their biological and clinical characteristics. A possible association between OAL and Chlamydia psittaci infection has suggested new mechanisms of lymphomagenesis, leading the way to specific targeted treatments. Similarly, the role of rituximab monoclonal antibody therapy and more conventional chemotherapy, as well as a wait-and-see policy in a few clearly defined situations, must be described in relation to the standard treatment option consisting of radiotherapy for low-grade lymphomas. The aims of this review are therefore to present the current knowledge on the biology of these lymphomas, their clinical features and prognostic factors, and finally the available treatment options.

Keywords::

• adnexal site
• antibiotic therapy
• Chlamydia psittaci
• NF-κB pathway
• non-Hodgkin’s lymphoma
• ocular site
• radiotherapy
• rituximab
• wait-and-see policy

Acknowledgements

Didier Decaudin is grateful to Anne Vincent-Salomon and Vincent Servois for providing histopathological and MRI data, respectively.

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.